Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer
Sixty patients with FIGO stage IIb, IIc, III and IV ovarian cancer were entered into a randomized Phase III study of cyclophosphamide 600 mg/m 2 with cisplatin 100 mg/m 2 , iproplatin 240 mg/m 2 or carboplatin 300 mg/m 2 . Dose modifications were made according to renal function and myelotoxicity. T...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer & clinical oncology 1988-09, Vol.24 (9), p.1471-1479 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1479 |
|---|---|
| container_issue | 9 |
| container_start_page | 1471 |
| container_title | European journal of cancer & clinical oncology |
| container_volume | 24 |
| creator | Anderson, H. Wagstaff, J. Crowther, D. Swindell, R. Lind, M.J. McGregor, J. Timms, M.S. Brown, D. Palmer, P. |
| description | Sixty patients with FIGO stage IIb, IIc, III and IV ovarian cancer were entered into a randomized Phase III study of cyclophosphamide
600 mg/m
2
with cisplatin
100 mg/m
2
, iproplatin
240 mg/m
2
or carboplatin
300 mg/m
2
. Dose modifications were made according to renal function and myelotoxicity. The arms containing carboplatin (CBDCA) and iproplatin (CHIP) were not shown to be significantly different from the cisplatin containing arm with regard to response rate, duration of response and survival.
Subjective toxicity showed that cisplatin and cyclophosphamide therapy was associated with more nausea and vomiting (
P = 0.0005). The duration of vomiting showed a significant increase with successive courses of chemotherapy for the cisplatin containing arm only (
P < 0.003). The cyclophosphamide/CHIP combination caused significantly more diarrhoea (
P < 0.0006). Alopecia was more severe (
P < 0.02), and neurotoxicity was more common, in patients who received cyclophosphamide and cisplatin (paraesthesiae
P = 0.0007, tinnitus
P < 0.00005, deafness
P = 0.0018).
All three combinations caused cumulative toxicity on haemoglobin (Hb) (
P < 0.001 for each treatment), leukocyte count (WCC) (
P < 0.0005 for each treatment), and platelet count (
P < 0.0005 for each treatment). The degree of fall in Hb for each course of therapy was greater in the cisplatin containing arm compared with the CHIP and CBDCA arms which were not significantly different from each other (
P = 0.0005). For WCC the cisplatin/cyclophosphamide regimen was significantly less toxic than CHIP/cyclophosphamide, with CBDCA/cyclophosphamide falling between the two and not being significantly different from either (
P = 0.0005). The CHIP containing arm caused more thrombocytopenia than the other arms which were of equal toxicity (
P < 0.0005).
Serum creatinine showed a gradual significant overall rise with each course of cisplatin/cyclophosphamide therapy (
P < 0.0005), whereas the CBDCA arm showed no change and the CHIP arm showed a small fall in serum creatinine after most courses of therapy.
This study showed that CHIP or CBDCA in combination with cyclophosphamide was less toxic than cisplatin/cyclophosphamide therapy with regard to alopecia, degree and duration of nausea and vomiting, renal toxicity, neurotoxicity and anaemia. The CHIP/cyclophosphamide regimen caused more thrombocytopenia and diarrhoea. The CHIP and CBDCA containing arms caused more leukopenia than the cisplatin containing regimen. Ei |
| doi_str_mv | 10.1016/0277-5379(88)90338-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15597049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0277537988903380</els_id><sourcerecordid>15597049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-30d993d969aff67d306ff2de9fa48b89d5f65972a5da7da95e5f92fdd58104c13</originalsourceid><addsrcrecordid>eNp9kU2O1DAQhb0ADcPADUDyAqFpiYATx4m9QRrCz4w0EixgbVXbZbVREgc73dAH4p44pNXsWNl-76uS6xUhz0r2umRl84ZVbVsI3qprKTeKcS4L9oBcnuVH5HFK3xmrZC34BbngTPCKtZfkdxeGCSLM_oB0Dr-88fORBkeNT1Of5fEVNRC3YX3Q6-7d--5mQ2G01E_xn3x792VD882EYevHLIaR_vTzjpqj6cO0C2naweAtLtCUfRzntBJgDzAatBSn_MTeQ0_DAaKH3G5x4hPy0EGf8OnpvCLfPn742t0W958_3XU394Wpy3YuOLNKcasaBc41reWsca6yqBzUciuVFa4Rqq1AWGgtKIHCqcpZK2TJalPyK_Jy7Zsn-7HHNOvBJ4N9DyOGfdKlyOWsVhmsV9DEkFJEp6foB4hHXTK9bEQv0eslei2l_rsRzXLZ81P__XZAey46rSP7L04-JAO9i3l6n85Yo1Sl6iZjb1cMcxYHj1Enk_PMEfqIZtY2-P__4w8OZayT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15597049</pqid></control><display><type>article</type><title>Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Anderson, H. ; Wagstaff, J. ; Crowther, D. ; Swindell, R. ; Lind, M.J. ; McGregor, J. ; Timms, M.S. ; Brown, D. ; Palmer, P.</creator><creatorcontrib>Anderson, H. ; Wagstaff, J. ; Crowther, D. ; Swindell, R. ; Lind, M.J. ; McGregor, J. ; Timms, M.S. ; Brown, D. ; Palmer, P.</creatorcontrib><description><![CDATA[Sixty patients with FIGO stage IIb, IIc, III and IV ovarian cancer were entered into a randomized Phase III study of cyclophosphamide
600 mg/m
2
with cisplatin
100 mg/m
2
, iproplatin
240 mg/m
2
or carboplatin
300 mg/m
2
. Dose modifications were made according to renal function and myelotoxicity. The arms containing carboplatin (CBDCA) and iproplatin (CHIP) were not shown to be significantly different from the cisplatin containing arm with regard to response rate, duration of response and survival.
Subjective toxicity showed that cisplatin and cyclophosphamide therapy was associated with more nausea and vomiting (
P = 0.0005). The duration of vomiting showed a significant increase with successive courses of chemotherapy for the cisplatin containing arm only (
P < 0.003). The cyclophosphamide/CHIP combination caused significantly more diarrhoea (
P < 0.0006). Alopecia was more severe (
P < 0.02), and neurotoxicity was more common, in patients who received cyclophosphamide and cisplatin (paraesthesiae
P = 0.0007, tinnitus
P < 0.00005, deafness
P = 0.0018).
All three combinations caused cumulative toxicity on haemoglobin (Hb) (
P < 0.001 for each treatment), leukocyte count (WCC) (
P < 0.0005 for each treatment), and platelet count (
P < 0.0005 for each treatment). The degree of fall in Hb for each course of therapy was greater in the cisplatin containing arm compared with the CHIP and CBDCA arms which were not significantly different from each other (
P = 0.0005). For WCC the cisplatin/cyclophosphamide regimen was significantly less toxic than CHIP/cyclophosphamide, with CBDCA/cyclophosphamide falling between the two and not being significantly different from either (
P = 0.0005). The CHIP containing arm caused more thrombocytopenia than the other arms which were of equal toxicity (
P < 0.0005).
Serum creatinine showed a gradual significant overall rise with each course of cisplatin/cyclophosphamide therapy (
P < 0.0005), whereas the CBDCA arm showed no change and the CHIP arm showed a small fall in serum creatinine after most courses of therapy.
This study showed that CHIP or CBDCA in combination with cyclophosphamide was less toxic than cisplatin/cyclophosphamide therapy with regard to alopecia, degree and duration of nausea and vomiting, renal toxicity, neurotoxicity and anaemia. The CHIP/cyclophosphamide regimen caused more thrombocytopenia and diarrhoea. The CHIP and CBDCA containing arms caused more leukopenia than the cisplatin containing regimen. Either iproplatin or carboplatin would be an acceptable alternative to cisplatin in chemotherapy regimens, and would result in reduced toxicity.]]></description><identifier>ISSN: 0277-5379</identifier><identifier>DOI: 10.1016/0277-5379(88)90338-0</identifier><identifier>PMID: 3053207</identifier><identifier>CODEN: EJCODS</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carboplatin ; Chemotherapy ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Clinical Trials as Topic ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Female ; Humans ; Leukocyte Count ; Medical sciences ; Middle Aged ; Organoplatinum Compounds - administration & dosage ; Organoplatinum Compounds - adverse effects ; Ovarian Neoplasms - drug therapy ; Pharmacology. Drug treatments ; Random Allocation ; Vomiting - chemically induced</subject><ispartof>European journal of cancer & clinical oncology, 1988-09, Vol.24 (9), p.1471-1479</ispartof><rights>1988</rights><rights>1989 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-30d993d969aff67d306ff2de9fa48b89d5f65972a5da7da95e5f92fdd58104c13</citedby><cites>FETCH-LOGICAL-c417t-30d993d969aff67d306ff2de9fa48b89d5f65972a5da7da95e5f92fdd58104c13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6992946$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3053207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anderson, H.</creatorcontrib><creatorcontrib>Wagstaff, J.</creatorcontrib><creatorcontrib>Crowther, D.</creatorcontrib><creatorcontrib>Swindell, R.</creatorcontrib><creatorcontrib>Lind, M.J.</creatorcontrib><creatorcontrib>McGregor, J.</creatorcontrib><creatorcontrib>Timms, M.S.</creatorcontrib><creatorcontrib>Brown, D.</creatorcontrib><creatorcontrib>Palmer, P.</creatorcontrib><title>Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer</title><title>European journal of cancer & clinical oncology</title><addtitle>Eur J Cancer Clin Oncol</addtitle><description><![CDATA[Sixty patients with FIGO stage IIb, IIc, III and IV ovarian cancer were entered into a randomized Phase III study of cyclophosphamide
600 mg/m
2
with cisplatin
100 mg/m
2
, iproplatin
240 mg/m
2
or carboplatin
300 mg/m
2
. Dose modifications were made according to renal function and myelotoxicity. The arms containing carboplatin (CBDCA) and iproplatin (CHIP) were not shown to be significantly different from the cisplatin containing arm with regard to response rate, duration of response and survival.
Subjective toxicity showed that cisplatin and cyclophosphamide therapy was associated with more nausea and vomiting (
P = 0.0005). The duration of vomiting showed a significant increase with successive courses of chemotherapy for the cisplatin containing arm only (
P < 0.003). The cyclophosphamide/CHIP combination caused significantly more diarrhoea (
P < 0.0006). Alopecia was more severe (
P < 0.02), and neurotoxicity was more common, in patients who received cyclophosphamide and cisplatin (paraesthesiae
P = 0.0007, tinnitus
P < 0.00005, deafness
P = 0.0018).
All three combinations caused cumulative toxicity on haemoglobin (Hb) (
P < 0.001 for each treatment), leukocyte count (WCC) (
P < 0.0005 for each treatment), and platelet count (
P < 0.0005 for each treatment). The degree of fall in Hb for each course of therapy was greater in the cisplatin containing arm compared with the CHIP and CBDCA arms which were not significantly different from each other (
P = 0.0005). For WCC the cisplatin/cyclophosphamide regimen was significantly less toxic than CHIP/cyclophosphamide, with CBDCA/cyclophosphamide falling between the two and not being significantly different from either (
P = 0.0005). The CHIP containing arm caused more thrombocytopenia than the other arms which were of equal toxicity (
P < 0.0005).
Serum creatinine showed a gradual significant overall rise with each course of cisplatin/cyclophosphamide therapy (
P < 0.0005), whereas the CBDCA arm showed no change and the CHIP arm showed a small fall in serum creatinine after most courses of therapy.
This study showed that CHIP or CBDCA in combination with cyclophosphamide was less toxic than cisplatin/cyclophosphamide therapy with regard to alopecia, degree and duration of nausea and vomiting, renal toxicity, neurotoxicity and anaemia. The CHIP/cyclophosphamide regimen caused more thrombocytopenia and diarrhoea. The CHIP and CBDCA containing arms caused more leukopenia than the cisplatin containing regimen. Either iproplatin or carboplatin would be an acceptable alternative to cisplatin in chemotherapy regimens, and would result in reduced toxicity.]]></description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carboplatin</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Clinical Trials as Topic</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Leukocyte Count</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Random Allocation</subject><subject>Vomiting - chemically induced</subject><issn>0277-5379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2O1DAQhb0ADcPADUDyAqFpiYATx4m9QRrCz4w0EixgbVXbZbVREgc73dAH4p44pNXsWNl-76uS6xUhz0r2umRl84ZVbVsI3qprKTeKcS4L9oBcnuVH5HFK3xmrZC34BbngTPCKtZfkdxeGCSLM_oB0Dr-88fORBkeNT1Of5fEVNRC3YX3Q6-7d--5mQ2G01E_xn3x792VD882EYevHLIaR_vTzjpqj6cO0C2naweAtLtCUfRzntBJgDzAatBSn_MTeQ0_DAaKH3G5x4hPy0EGf8OnpvCLfPn742t0W958_3XU394Wpy3YuOLNKcasaBc41reWsca6yqBzUciuVFa4Rqq1AWGgtKIHCqcpZK2TJalPyK_Jy7Zsn-7HHNOvBJ4N9DyOGfdKlyOWsVhmsV9DEkFJEp6foB4hHXTK9bEQv0eslei2l_rsRzXLZ81P__XZAey46rSP7L04-JAO9i3l6n85Yo1Sl6iZjb1cMcxYHj1Enk_PMEfqIZtY2-P__4w8OZayT</recordid><startdate>19880901</startdate><enddate>19880901</enddate><creator>Anderson, H.</creator><creator>Wagstaff, J.</creator><creator>Crowther, D.</creator><creator>Swindell, R.</creator><creator>Lind, M.J.</creator><creator>McGregor, J.</creator><creator>Timms, M.S.</creator><creator>Brown, D.</creator><creator>Palmer, P.</creator><general>Elsevier Ltd</general><general>Pergamon Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19880901</creationdate><title>Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer</title><author>Anderson, H. ; Wagstaff, J. ; Crowther, D. ; Swindell, R. ; Lind, M.J. ; McGregor, J. ; Timms, M.S. ; Brown, D. ; Palmer, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-30d993d969aff67d306ff2de9fa48b89d5f65972a5da7da95e5f92fdd58104c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carboplatin</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Clinical Trials as Topic</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Leukocyte Count</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Random Allocation</topic><topic>Vomiting - chemically induced</topic><toplevel>online_resources</toplevel><creatorcontrib>Anderson, H.</creatorcontrib><creatorcontrib>Wagstaff, J.</creatorcontrib><creatorcontrib>Crowther, D.</creatorcontrib><creatorcontrib>Swindell, R.</creatorcontrib><creatorcontrib>Lind, M.J.</creatorcontrib><creatorcontrib>McGregor, J.</creatorcontrib><creatorcontrib>Timms, M.S.</creatorcontrib><creatorcontrib>Brown, D.</creatorcontrib><creatorcontrib>Palmer, P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>European journal of cancer & clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anderson, H.</au><au>Wagstaff, J.</au><au>Crowther, D.</au><au>Swindell, R.</au><au>Lind, M.J.</au><au>McGregor, J.</au><au>Timms, M.S.</au><au>Brown, D.</au><au>Palmer, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer</atitle><jtitle>European journal of cancer & clinical oncology</jtitle><addtitle>Eur J Cancer Clin Oncol</addtitle><date>1988-09-01</date><risdate>1988</risdate><volume>24</volume><issue>9</issue><spage>1471</spage><epage>1479</epage><pages>1471-1479</pages><issn>0277-5379</issn><coden>EJCODS</coden><abstract><![CDATA[Sixty patients with FIGO stage IIb, IIc, III and IV ovarian cancer were entered into a randomized Phase III study of cyclophosphamide
600 mg/m
2
with cisplatin
100 mg/m
2
, iproplatin
240 mg/m
2
or carboplatin
300 mg/m
2
. Dose modifications were made according to renal function and myelotoxicity. The arms containing carboplatin (CBDCA) and iproplatin (CHIP) were not shown to be significantly different from the cisplatin containing arm with regard to response rate, duration of response and survival.
Subjective toxicity showed that cisplatin and cyclophosphamide therapy was associated with more nausea and vomiting (
P = 0.0005). The duration of vomiting showed a significant increase with successive courses of chemotherapy for the cisplatin containing arm only (
P < 0.003). The cyclophosphamide/CHIP combination caused significantly more diarrhoea (
P < 0.0006). Alopecia was more severe (
P < 0.02), and neurotoxicity was more common, in patients who received cyclophosphamide and cisplatin (paraesthesiae
P = 0.0007, tinnitus
P < 0.00005, deafness
P = 0.0018).
All three combinations caused cumulative toxicity on haemoglobin (Hb) (
P < 0.001 for each treatment), leukocyte count (WCC) (
P < 0.0005 for each treatment), and platelet count (
P < 0.0005 for each treatment). The degree of fall in Hb for each course of therapy was greater in the cisplatin containing arm compared with the CHIP and CBDCA arms which were not significantly different from each other (
P = 0.0005). For WCC the cisplatin/cyclophosphamide regimen was significantly less toxic than CHIP/cyclophosphamide, with CBDCA/cyclophosphamide falling between the two and not being significantly different from either (
P = 0.0005). The CHIP containing arm caused more thrombocytopenia than the other arms which were of equal toxicity (
P < 0.0005).
Serum creatinine showed a gradual significant overall rise with each course of cisplatin/cyclophosphamide therapy (
P < 0.0005), whereas the CBDCA arm showed no change and the CHIP arm showed a small fall in serum creatinine after most courses of therapy.
This study showed that CHIP or CBDCA in combination with cyclophosphamide was less toxic than cisplatin/cyclophosphamide therapy with regard to alopecia, degree and duration of nausea and vomiting, renal toxicity, neurotoxicity and anaemia. The CHIP/cyclophosphamide regimen caused more thrombocytopenia and diarrhoea. The CHIP and CBDCA containing arms caused more leukopenia than the cisplatin containing regimen. Either iproplatin or carboplatin would be an acceptable alternative to cisplatin in chemotherapy regimens, and would result in reduced toxicity.]]></abstract><cop>Oxford</cop><cop>New York, NY</cop><pub>Elsevier Ltd</pub><pmid>3053207</pmid><doi>10.1016/0277-5379(88)90338-0</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-5379 |
| ispartof | European journal of cancer & clinical oncology, 1988-09, Vol.24 (9), p.1471-1479 |
| issn | 0277-5379 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15597049 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carboplatin Chemotherapy Cisplatin - administration & dosage Cisplatin - adverse effects Clinical Trials as Topic Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Female Humans Leukocyte Count Medical sciences Middle Aged Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Ovarian Neoplasms - drug therapy Pharmacology. Drug treatments Random Allocation Vomiting - chemically induced |
| title | Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T23%3A58%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20toxicity%20of%20cisplatin,%20carboplatin%20(CBDCA)%20and%20iproplatin%20(CHIP)%20in%20combination%20with%20cyclophosphamide%20in%20patients%20with%20advanced%20epithelial%20ovarian%20cancer&rft.jtitle=European%20journal%20of%20cancer%20&%20clinical%20oncology&rft.au=Anderson,%20H.&rft.date=1988-09-01&rft.volume=24&rft.issue=9&rft.spage=1471&rft.epage=1479&rft.pages=1471-1479&rft.issn=0277-5379&rft.coden=EJCODS&rft_id=info:doi/10.1016/0277-5379(88)90338-0&rft_dat=%3Cproquest_cross%3E15597049%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15597049&rft_id=info:pmid/3053207&rft_els_id=0277537988903380&rfr_iscdi=true |